Stroke is the third largest cause of death and the single largest cause of adult disability in the developed world. The University of Glasgow and ReNeuron are advancing their clinical trial for stroke patients using neuronal stem cells. Approved by the UK Medicines and Healthcare Products Regulatory Agency (MHRA), the procedure involves expanding the stem cells in-vitro [to clinically relevant numbers] and then transplanting them into the individual. Professor Keith Muir, principal investigator in the trial, said: “We are very pleased that the trial is progressing well and that all the patients treated so far have shown no adverse effects.”
We believe that the expansion of stem cells in-vitro followed by transplantation will be the the gold standard of stem cell treatments. Ideally, the best stem cells to be used in such treatments are autologous in nature – meaning the stem cells are derived from the patient’s own body. Autologous stem cells eliminate the possibility of rejection and minimize significantly patient dependency on immuno-suppressant drugs.
To view the full article, click here.
The future of Regenerative Medicine is now™.